August 16, 2011
Bexion Pharmaceuticals announced today that it has been awarded the second year of their $1.5M Phase II Small Business Innovation Research (SBIR) grant by the
National Cancer Institute (NCI). The grant entitled “SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme” was awarded September 28, 2010 for a two year period. These newly awarded funds were released to Bexion based on the significant progress achieved in the first year of the award and will be utilized to complete an Investigational New Drug (IND) data set for the lead compound, BXQ-350, in glioma, a type of brain cancer.
“The funding and support from NCI are essential to meeting our aggressive development timeline,” stated Dr. Ray Takigiku, Bexion’s co-founder and CEO. “Our goal is to be in Phase I clinical trials in 2012”.
BXQ-350 is a novel nanovesicle composed of the human lysosomal protein Saposin C, and the lipid dioleoylphosphatidylserine (DOPS). This basic technology (dubbed “SapC-DOPS”) has shown preclinical efficacy against gliomas (GBM), as well as other refractory tumors including pancreatic cancer, and neuroblastomas. BXQ-350 has preferential affinity for tumors by targeting their phosphatidylserine-enriched membranes. With targeting, these nanovesicles also appear to selectively induce tumor apoptosis (cell-death).
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a privately owned company focused on the development and commercialization of innovative cures for cancer. Initial products are based on a proprietary platform technology licensed from Cincinnati Children’s Hospital Medical Center. The technology has demonstrated potential for development as therapeutics, diagnostic and surgical imaging reagents, and as a tumor-targeting carrier for other pharmaceutical agents, such as oligonucleotides. For more information on Bexion and BXQ-350, visit www.bexionpharma.com.
Margaret van Gilse
VP, Business Development
Bexion Pharmaceuticals, LLC
632 Russell Street
Covington, KY 41011
Phone: (513) 833-7065